New hope offered when CAR-T fails: experimental drug targets tough lymphoma cases

NCT ID NCT07453095

Summary

This study tests an experimental drug called glofitamab for people with mantle cell lymphoma whose cancer didn't respond well enough or came back after CAR-T cell therapy. About 41 participants will receive the drug to see if it can shrink their cancer and how safe it is. The goal is to find a new treatment option for patients who have already tried this advanced therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia

    Palermo, Italy

    Contact Email: •••••@•••••

    Contact

  • A.O.U. Città della Salute e della Scienza - Ematologia Universitaria

    Torino, Italy

    Contact Email: •••••@•••••

    Contact

  • AOU SS. Antonio e Biagio e Cesare Arrigo - SCDU Ematologia

    Alessandria, Italy

    Contact Email: •••••@•••••

    Contact

  • ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia

    Milan, Italy

    Contact Email: •••••@•••••

    Contact

  • ASST Spedali Civili - Ematologia

    Brescia, Italy

    Contact Email: •••••@•••••

    Contact

  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

    Florence, Italy

    Contact Email: •••••@•••••

    Contact

  • Azienda Ospedaliera Universitaria Integrata di Verona - U.O. Ematologia

    Verona, Italy

    Contact Email: •••••@•••••

    Contact

  • Azienda Ospedaliera Universitaria Pisana - U.O. Ematologia

    Pisa, Italy

    Contact Email: •••••@•••••

    Contact

  • Grande Ospedale Metropolitano Bianchi Melacrino Morelli - C.T.M.O.

    Reggio Calabria, Italy

    Contact Email: •••••@•••••

    Contact

  • Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia - Ematologia e terapie cellulari

    Genova, Italy

    Contact Email: •••••@•••••

    Contact

  • P.O. Spirito Santo di Pescara - UOC Ematologia Dipartimento Oncologico Ematologico - ASL Pescara

    Pescara, Italy

    Contact Email: •••••@•••••

    Contact

  • Policlinico S.Orsola-Malpighi - Istituto di Ematologia Seragnoli

    Bologna, Italy

    Contact Email: •••••@•••••

    Contact

  • Policlinico Umberto I - Universitа "La Sapienza" - Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione

    Roma, Italy

    Contact Email: •••••@•••••

    Contact

  • ULSS 8 Berica - Ospedale S. Bortolo - Ematologia

    Vicenza, Italy

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.